


Review

Harnessing Artificial Intelligence for the Diagnosis, Treatment and Research of Multiple Sclerosis

Manisha S. Patil ^{1,*}, Linda Y. Lin ¹, Rachel K. Ford ¹, Elizaveta J. James ¹, Stella Morton ¹, Felix Marsh-Wakefield ^{2,3} , Simon Hawke ^{1,4} and Georges E. Grau ^{1,*}

¹ Vascular Immunology Unit, School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2050, Australia; ylin8829@uni.sydney.edu.au (L.Y.L.); rachelford01@hotmail.com (R.K.F.); ejam8487@uni.sydney.edu.au (E.J.J.); smor0849@uni.sydney.edu.au (S.M.); simon.hawke@sydney.edu.au (S.H.)

² Liver Injury & Cancer Program, Centenary Institute, Sydney, NSW 2050, Australia; felix.marsh-wakefield@sydney.edu.au

³ Human Immunology Laboratory, School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2050, Australia

⁴ Central West Neurology and Neurosurgery, Orange, NSW 2800, Australia

* Correspondence: manisha.patil@sydney.edu.au (M.S.P.); ggrau@med.usyd.edu.au (G.E.G.)

Abstract: Multiple sclerosis (MS) is an autoimmune disease of the central nervous system affecting over 2.8 million people around the world. Artificial intelligence (AI) is becoming increasingly utilised in many areas, including patient care for MS. AI is revolutionising the diagnosis and treatment of MS by enhancing the accuracy and efficiency of both processes. AI algorithms, particularly those based on machine learning, are being used to analyse medical imaging data, such as MRI scans, to detect early signs of MS, monitor disease progression and assess patient treatment response with greater precision. AI can help identify subtle changes in the brain and spinal cord that may be missed by human clinicians, leading to earlier diagnosis and more personalised treatment plans. Additionally, AI is being employed to predict disease outcomes, which could allow clinicians to tailor therapies for individual patients based on their unique disease characteristics. In drug development, AI is accelerating the identification of potential therapeutic targets and the optimisation of clinical trial designs, potentially leading to faster development of new treatments for MS. AI is also playing a critical role in MS fundamental research by promoting efficient analysis of vast amounts of single-cell data. Through these advancements, AI could improve the overall management of MS, offering more timely interventions and better patient outcomes. In this review, we discuss these topics and whether the influence of AI on diagnosis, treatment and research of MS can change the future of this field.

Keywords: multiple sclerosis; artificial intelligence; machine learning; image analysis; risk prediction models; personalised treatment; drug discovery; single-cell analysis



Academic Editor: Maurizio A. Leone

Received: 17 March 2025

Revised: 23 April 2025

Accepted: 26 April 2025

Published: 29 April 2025

Citation: Patil, M.S.; Lin, L.Y.; Ford, R.K.; James, E.J.; Morton, S.; Marsh-Wakefield, F.; Hawke, S.; Grau, G.E. Harnessing Artificial Intelligence for the Diagnosis, Treatment and Research of Multiple Sclerosis.

Sclerosis **2025**, *3*, 15. <https://doi.org/10.3390/sclerosis3020015>

Copyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) affecting the brain, spinal cord and optic nerve. Over 2.8 million people have MS worldwide, with female preponderance and most diagnosed between the ages of 18 to 40 years [1]. People with MS (PwMS) commonly present periods of relapses followed by remissions and experience debilitating and neurological symptoms as the disease worsens [2]. This occurs when the immune system attacks the myelin surrounding nerve fibres, resulting in disrupted nerve signal transmission and subsequent injury and lesion formation in the

brain. Disease-modifying therapies (DMT) have become the cornerstone treatment for reducing inflammation and relapses, subsiding new lesion formation and slowing disease progression [3]. Although MS is a complex chronic disease with no cure, advancements in research into the causes, early diagnosis and DMT have significantly improved disease management and quality of life for PwMS.

Artificial intelligence (AI) is a rapidly evolving technology that is transforming the healthcare industry and is quickly becoming an integral part of our daily lives. It involves the ability of machines to learn, analyse, comprehend, reason, solve problems and make decisions that are otherwise performed by humans [4]. AI is changing the landscape for diagnosis and treatment of PwMS by employing machines to analyse medical imaging data, such as MRI scans, to detect early signs of MS and monitor disease progression with greater precision. In this review, we discuss how accurately AI algorithms determine MS prognosis compared to clinicians and their efficiency to predict disease outcomes (Figure 1). Furthermore, AI could be exploited to provide personalised treatment plans for MS patients that tailor therapies specifically to each patients' disease characteristics. In addition, we explore the role for AI in drug development and single-cell analysis to accelerate the search of potential therapeutic targets that could lead to new DMT for PwMS. Through these advancements, AI could improve overall management of MS, offering improved timely interventions and better outcomes for patients.




Figure 1. A brief summary of this review. Five topics are discussed: MS diagnosis and monitoring, modelling MS prediction, drug discovery, personalised medicine and fundamental research using single-cell data. MS: multiple sclerosis, AI: artificial intelligence, MRI: magnetic resonance imaging, EDSS: expanded disability status scale, OCT: optical coherence tomography, PET: positron emission tomography, MRS: magnetic resonance spectroscopy.

2. AI-Assisted Medical Data Analysis for MS Diagnosis and Monitoring

2.1. AI Analysis of MRI Data

PwMS commonly experience symptoms of fatigue, sleeping difficulty, vision impairment, limb pain and tingling, bladder and bowel issues and ambulatory impairment, though MS is clinically diagnosed by evidence of relapses or lesions in the brain [5,6].

Evaluation of lesion size and numbers using cerebral magnetic resonance imaging (MRI) is part of the daily clinical routine that is not only crucial for diagnosis but also monitoring disease progression and treatment response. Multiple studies have integrated AI into disease diagnosis and prognosis with many showing promising results. AI models have been trained to differentiate between MS and healthy MRI-scanned brains where one study found 91% accuracy when using a sea-horse optimiser algorithm while another reported 98% sensitivity, specificity and accuracy with an improved convolutional neural network (CNN) that combined a parametric rectified linear unit and a dropout method [7–9].

Relapse-remitting MS (RRMS) is the most common form of MS diagnosed in about 85% of PwMS and is caused by periods of symptom flare-ups followed by recovery [10]. When MRI data from RRMS patients were trained in a CNN, 95% accuracy was obtained for white and grey matter lesions, while this reduced to 82% accuracy for T2 lesions [11]. Similarly, Coronado et al., applied multispectral MRI data from RRMS patients in a deep learning CNN which provided accurate segmentation of gadolinium-enhancing lesions when five multispectral contrast images were used and lesion volume was greater than 70 mm³ [12]. However, another automated deep learning neural network called CLAIMS detected leukocortical and subpial lesions with 70–83% sensitivity when using only T1-weighted contrast images and provided more accurate results compared to T2-weighted contrasts [13]. These differences could be attributed to the strength of the MRI machine as CLAIMS used a 7T MRI scanner which provided ultra-high resolution T2-weighted and T1-weighted 3D magnetisation-prepared two rapid gradient-echoes (MP2RAGE), while the former study acquired MRI data at 3T. This shows that AI accuracy and efficiency could be impacted by the quality of MRI data.

Indeed, the lesion location is another contributing factor, as AI models have been exclusively trained to identify white matter lesions in MR images by setting known lesion detection parameters [14,15]. Additionally, Eshaghi and colleagues developed an unsupervised machine learning (ML) algorithm called Subtype and Staging Inference (SuStaIn) to identify lesions and abnormal patterns of grey and normal-appearing white matter MRI, which enabled accurate identification of MS subtypes [16]. Studies have also shown the ability for AI models to identify non-active and active brain lesions in MRI data, which provides vital information about MS disease progression. Gadolinium T1-weighted MRI is commonly used to detect active lesions and when trained with deep learning AI models, 95% accuracy was achieved for differentiating active and non-active plaques [17]. However, accuracy is reduced when using non-contrast FLAIR MRI [18]. One study showed ML models accurately identified active and non-active lesions in diffusion-weighted images, an advanced form of MRI [19]. Even thalamic volume loss, known to be a marker for neurodegeneration, was detected in 7 s by a deep learning model called DeepGRAI using T2-FLAIR MRI [20]. Furthermore, an experiment revealed that AI-assisted MR image analysis for lesions significantly reduced reporting time compared to radiologists at initial and six-week follow-up [21]. Another study also reported greater accuracy for lesion detection with their AI tool, iQ-MS, showing 93.3% sensitivity compared to radiology reports which had 58.3% sensitivity, even though specificity was equal between both [22]. The accuracy and speed by which AI can identify MS pathology is remarkable and proven to be better than clinicians.

2.2. EDSS, OCT and PET Data Analysis

Studies have shown the capability for AI to predict MS disease progression using multiple forms of clinical data. In the ML algorithm, SuStaIn, the combinatorial inclusion of clinical data such as Expanded Disability Status Scale (EDSS), walking and finger dexterity results with MRI predicted disease progression [16]. Another study also combined MRI

with age and EDSS score in a deep learning predictor to identify 2-year clinical disability probability in MS patients [23]. Interestingly, retinal imaging known as optical coherence tomography (OCT) can also be utilised to diagnose MS as the 2008 Optic Neuritis Treatment Trial showed a correlation between decreased visual acuity and MRI lesions [24]. AI models trained to identify discriminating results in the OCT of the retinal structure from healthy and MS patients revealed high accuracy, sensitivity and specificity for MS diagnosis [25–28]. Interestingly, myelin content in the brain, usually measured by positron emission tomography (PET), has been predicted with Generative Adversarial Networks using multimodal MR images [29]. This shows that AI can be trained to identify and diagnose MS using various forms of medical data.

2.3. Future Directions for MS Diagnosis

An additional method used to identify MS that has not been experimented with AI is histopathology. This involves assessing MS plaques and lesions for immune cell infiltration and myelin degradation [5]. Our literature search found no published studies utilising AI to predict MS based on histopathology but this may be a future direction to identify MS subtypes. Cancer studies have already developed deep learning algorithms to detect tumours on histological slides which demonstrated high accuracy and reduced time for diagnosis as well as high throughput analysis compared to pathologists [30–34]. Similarly, AI could be trained to scrutinise MS histopathology slides to detect subtle changes in the brain and spinal cord that could be missed by humans. Compared to cancer, MS histology requires brain biopsy under general anaesthesia or from post-mortem tissue. Thus, AI-assisted analysis of these slides could be implemented to identify MS subtypes and new markers for MS which can increase our knowledge about MS pathogenesis and lead to potential new therapeutic targets [35]. More research is required to establish an ideal method to combine AI with MS histopathology for meticulous and efficient image analysis beyond the human eye.

Another consideration for the future of AI in MS is the ability to differentiate MS lesions from other brain lesions associated with stroke, tumours and infectious diseases as this could lead to misdiagnoses. Numerous cases have been reported whereby MRI lesions are recognised as gliomas or MS plaques leading to the wrong diagnosis and treatment for MS or late detection for cancer patients [36–38]. Indeed, AI provides more accurate diagnosis for MS compared to clinicians but there are still cases where it is difficult for ML to differentiate MS lesions from other neurodegenerative diseases [39]. Hence other methods are required to confirm diagnosis, such as reviewing patient symptoms and close follow-up, analysing cerebrospinal fluid (CSF) or CNS biopsy and performing PET scan or magnetic resonance spectroscopy (MRS) [36,38]. MRS improves analysis of lesions as it measures biochemical changes in normal-appearing white brain matter and is often used in conjunction with MRI to better assess MS prognosis [40,41]. A study used MS and brain tumour MRS data and applied various ML methods to distinguish MS lesions from tumours [42]. Remarkably, the results showed that an artificial neural network had 100% accuracy, specificity and sensitivity for differentiating MS lesions and brain tumours. This confirms that AI can identify different diseases, possibly better than clinicians, providing early and accurate diagnosis for patients, thus expediting their treatment. Ultimately, this section showcases significant results of accurate and efficient MS diagnosis and disease prognosis using AI which presents a positive and promising outlook on implementing AI in the future for patient care.

3. AI-Modelling to Predict Risk of MS, Progression of MS and Treatment Response

Given the diverse clinical presentations and unpredictable disease progression in MS, it is imperative to mitigate long-term disability. Traditional diagnostic frameworks encounter challenges due to the subjective nature of symptom reporting and constrained healthcare accessibility, particularly in resource-limited settings [43]. The emergence of AI and ML has introduced innovative approaches to early disease prediction [44]. AI-driven diagnostic systems offer promising solutions by enhancing clinical accuracy and supporting evidence-based decision-making [45].

3.1. AI Assists in Diagnostic Assessments and Prevents Diagnostic Delays in MS Diagnosis

One of the primary contributions of AI in MS diagnosis is its ability to manage diagnostic uncertainty through fuzzy logic. Patients may provide imprecise or incomplete descriptions of their conditions, introducing variability into the diagnostic process [46]. Fuzzy logic overcomes this issue by assigning degrees of membership to symptoms, facilitating a more refined interpretation of patient-reported data [46]. This enhances the reliability of diagnostic assessments despite subjective input variability. Another contribution of AI is the ability of expert systems to replicate human reasoning, leveraging structured knowledge bases and predefined inference rules. These systems integrate well-established clinical indicators of MS, such as optic neuritis, brainstem dysfunction and spinal cord involvement [47]. Expert systems can identify high-risk individuals through evaluation of symptoms and demographic data, which prevents diagnostic delays and clinical referrals [46].

3.2. Different ML Techniques Available to Analyse Clinical Datasets for MS

In a recent study, ML techniques, a subtype of AI tools, were used to differentiate between MS patients and healthy individuals in which socio-demographic characteristics and environmental factors were gathered from 100 MS patients and 100 controls [48]. Six ML models were evaluated for their ability to predict MS: Naive Bayes (NB), Support Vector Machine (SVM), Least Square Support Vector Machine (LSSVM), Random Forest (RF), Logistic Regression (LR), and Linear Discriminant Analysis (LDA). NB reported high sensitivity (79%) but lower specificity, while SVM performed well in non-linear scenarios with kernel functions [48]. RF was the most robust model, achieving the highest accuracy (68%) whilst identifying key predictors, such as age between 20–40 and females [48]. Performance metrics like sensitivity and specificity can identify the strengths and limitations of each model, highlighting the ability of ML in analysing complex clinical datasets for MS [49].

3.3. Combination of ML and Clinicians Enhances the Prediction of MS Progression

The predictive ability of ML and AI in MS is enhanced by the well-established pathological processes, such as immune system dysfunction and BBB disruption. Levels of innate immune cells are altered in the CSF and the BBB disruption facilitates infiltration of proteins and immune cells, which exacerbates the inflammatory and demyelinating processes [50,51]. By identifying routine blood markers, AI models can classify certain individuals at heightened risk of MS [52]. Hybrid approaches that combine ML predictions with human expertise offer an innovative solution to the limitations of standalone systems. Studies involving medical students as evaluators have shown that human predictions improve significantly when combined with algorithmic outputs such as predictions from an RF model [53]. These results suggest that human intuition and algorithmic classification can complement each other to enhance the reliability of MS progression forecasts [53].

3.4. Monitoring Treatment Response with ML Models

Current applications of longitudinal ML methods for monitoring treatment response remain limited due to several challenges. First, ML models must be optimised in cross-sectional settings before extending their application to longitudinal data [54,55]. Second, AI algorithms require large-scale datasets comprising thousands of subjects, which are difficult to acquire [54]. Third, the emergence of personalised DMT for MS requires precise and reliable tools to assess motor and cognitive disability progression, which ML may contribute to [56].

3.5. Utilisation of AI in MS Prognosis

AI and ML are revolutionising the prognosis of MS by providing advanced tools that overcome the limitations of conventional approaches. A combination of algorithmic predictions and clinical expertise presents a robust framework for achieving greater accuracy and personalisation in patient care. These innovations have the potential to enhance clinical outcomes, refine treatment strategies and transform the landscape of medical decision-making in MS. AI in MS faces significant challenges, particularly the lack of large, diverse datasets available to train robust models capable of addressing disease variability [57,58]. Open science initiatives and adherence to FAIR principles (Findable, Accessible, Interoperable, Reusable) are critical for fostering collaboration and ensuring broader applicability [59]. A recent study by Placido and colleagues utilised the application of AI to predict the risk of pancreatic cancer in large, longitudinal datasets containing 6 million patient records in Denmark and 3 million patient records in the United States [60]. Using an ML model trained on comprehensive electronic health records (EHRs), the 1000 highest-risk patients in a hypothetical population of 1 million were identified, predicting that approximately 320 would develop pancreatic cancer within a 12-month interval [60]. The model also identified high-risk individuals who might not have been flagged by traditional clinical practices, enabling earlier surveillance [60]. While some progress has been made for MS, the availability of large public datasets remains limited [61].

3.6. Applications of ML Models to MRI

In addition to conventional MRI features, ML models applied to radiomics have garnered interest, particularly in differentiating MS from other neurological disorders with similar radiological features [62,63]. A radiomics-based model was designed to differentiate RRMS from neuropsychiatric systemic lupus erythematosus (NPSLE) using MRI. Radiomics extracts high-dimensional imaging features, including those overlooked by radiologists, to capture subtle differences between diseases [64]. RRMS and NPSLE share features like white matter hyperintensities, with radiomics analysis highlighting distinguishing characteristics in lesion morphology, intensity and texture [65–67]. ML algorithms enhanced the model's accuracy, achieving robust performance with minimal misclassifications [64]. This multi-lesion merging strategy outperformed single-lesion approaches and radiologists, making it a valuable tool for improving differential diagnosis and preventing misclassification [64].

3.7. Statistical Modelling Improves Prediction of Disability Progression in MS

Furthermore, the incorporation of statistical modelling, such as use of Markov models, to current AI applications allows prediction of short-term disability progression in MS [68]. In conventional survival models, patients are excluded if they do not reach the disability threshold within the study duration, which limits disease progression data [69]. To overcome these limitations, the Markov model uses the EDSS score to focus on the transitions between distinct states of disability, ensuring all clinical information, including transient

changes in disability, is incorporated into the analysis [68]. By analysing sequential EDSS scores with clinical and imaging data, the model can generate a potential progression pathway for individuals [68,70,71]. This allows clinicians and researchers to compare outcomes across different patient profiles and to better tailor interventions to individual needs.

4. AI-Assisted Drug Discovery

When it comes to the implementation of AI techniques in MS drug discovery, most methods have not been widely realised. Drug development is costly, as the development of a new FDA-approved drug can cost upwards of USD 802 million [72] and is also restrained by the “one gene, one drug, one disease” hypothesis. The frequent failure of randomised control trials, multiple drug–target interactions, unintended side-effects and off-target toxicities also cloud the smooth development of new therapies [72]. AI techniques such as deep-learning and ML provide a solution to this through drug repurposing and re-organisation of existing data on drugs and their targets. Other techniques more geared towards prediction have been employed in other diseases which has laid the groundwork for their potential application in MS drug discovery [73,74].

4.1. Deep Learning and ML Methods for Drug Repurposing and New Therapeutic Targets

DeepDTnet was developed as a deep learning method for identifying new targets and for repurposing existing therapies [72]. It was successfully applied to MS drug discovery, validating topotecan as a new inhibitor of ROR- γ t, a hormone receptor that regulates inflammation in the pathogenesis of MS, in a ligand-dependent manner. To validate this interaction, it used a heterogeneous drug–gene–disease network composed of 15 chemical, genomic, phenotypic and cellular network profiles. The network was trained on 732 existing U.S. FDA-approved, small-molecule drugs. Topotecan also had a therapeutic effect on mice in in vivo experiments. The model was particularly viable as the low dimensionality of the t-SNE vectors created provided information on all drug targets, without erroneous exclusions. It also was able to use positive-unlabelled matrix completion to exclude negative sample input, when two drugs shared a target. The model covered four dominant target families in MS drug discovery: GPCRs, kinases, NRs and ICs [72].

Another ML pathway, justified with Leave-One-Out-Cross Validation (LOOCV), was similarly employed to perform drug repositioning and to understand the defective pathways that underpin MS [75]. Two publicly available microarray datasets were acquired from naïve CD4⁺T-cells, using 54, 675 probes and 113 samples from healthy and MS samples. A second, independent microarray dataset was used for validation purposes, comprised of 20 samples and similarly derived from T-cells. For the second dataset, MS samples were taken from relapsed patients. From this, an expanded list of predictive genes was generated to reflect biological pathways involved in the pathology of MS. Posterior gene discriminatory power, paired with LOOCV and a distance-based classifier was used to identify a smaller subset of gene signatures with predictive accuracy, and to remove redundancies caused by the study’s under-determined phenotype prediction problem. This subset was tested against the independent dataset to confirm druggable targets. Viral infections and processes such as Th17 cell differentiation and CD28 co-stimulation were considered relevant in the progression of MS [75]. This information led to the discovery of new therapeutic targets associated with these processes, such as Trichostatin A and other histone deacetylase (HDAC) inhibitors.

In addition to the discovery-based applications, AI can assist in testing the broader effects of new therapies. A network model of the genes that underpin T-cell activation in healthy patients compared to MS patients was developed. The network model used data obtained through the assessment of gene expression levels from 20 genes using a

quantitative real-time PCR. The analysis involved a cohort of 104 subjects, composed of MS patients and healthy controls. The model combines these gene expression data, results from PBMC stimulation studies, and Jagged-1 and IFN- β stimulation assays to uncover how certain molecular interactions contribute to T-cell activation in MS. An MS mouse model was also used to validate Jagged-1 receptors as therapeutic targets, which reduce inflammation by influencing T-cell differentiation. A total of 13 new biologically significant and targetable links, including Jagged-1, were identified in their network [76].

4.2. Future Directions for Drug Discovery

Additional recent literature outlines other AI techniques and models which may be appropriate for future application in MS drug discovery. For instance, a novel Bayesian formulation combined dimensionality reduction, matrix factorisation and binary classification [75]. The model was built by encoding the chemical similarity between drug compounds and the genomic similarity between target proteins. A variational approximation was applied to allow for efficient approximation of the complex structure of these drug–target relationships. The joint Bayesian formulation was used to project drugs and targets into a subspace and then chemoinformatic and bioinformatic techniques were employed to find similarities, inferring new drug–target interactions [73] for further testing in vitro or in vivo. Drug–target interactions have also been explored under the bipartite model concept, “NetLapRLS” [74]. In an effort to analyse both well-known, labelled information and unidentified yet potentially useful information in the system, a semi-supervised learning model was used, including heterogeneous publicly available biological datasets. This included a chemical structure similarity matrix and a genomic similarity matrix which were enhanced by a set of known drug–protein interactions. This study was able to predict certain drug–target interactions involving enzymes, ion channels, GPCRs, and nuclear receptors [74]. The team was also able to verify some of these more strongly predicted interactions using existing KEGG databases to prove the efficacy of the method.

Other examples include a more specific analysis of the bioactivity and structure of the potential molecular drug candidates. Chemical ranking methods have also been an object of investigation as a means to comb through extensive, existing molecular databases for viable candidates for pharmaceutical application—a task that is difficult due to the high volume of data [77]. Computational docking has also been surveyed for its potential in evaluating drug candidates [78]. It involves predicting the best orientation and conformation of a molecule, and possible drug candidate, when attached to a protein of interest. A list of binding poses is assessed and then given a rank using a scoring function. The result is a list of ranked, potential ligands in order of stability, which allows for the algorithm’s high throughput production of feasible drug candidates.

Many ML-based techniques are currently being examined in MS and in other diseases. Most involve the repurposing of existing drugs, the evaluation of drug efficacy, analysis of drug–protein interactions, and the optimisation of the bioactivity of molecules based on, for instance, their structure. It seems clear that there is strong potential for the optimisation of these techniques further to suit the unique pathogenic profile of MS.

5. AI-Assisted Personalised Medicine Approach to MS Care

Disease course and response to DMT can vary significantly, meaning the management of each person’s MS must be adaptive and tailored to individual needs. This approach is referred to as personalised medicine, where an individual’s genetics, environment and lifestyle are incorporated in the management of their MS [79]. More recently a role for AI in personalised medicine for MS has emerged, including using AI models to process and analyse large patient specific datasets including genetic profiles, biomarkers and clinical

history to tailor treatment plans. AI-assisted analyses of these datasets could be used to develop digital patient pathways to inform clinical decision-making. There is also a role for AI in strengthening knowledge about MS and facilitating accessible communication between clinicians and PwMS to improve treatment adherence and overall health outcomes.

5.1. AI-Assisted Digital Patient Pathways and Digital Twins

The development of AI-assisted digital patient pathways could help support personalised treatment decision making. Large language models (LLM) could be used to process and analyse large datasets such as patient records, and treatment guidelines could aid in selecting DMT that are likely to be the most effective [79]. An extensive integrative framework for the design of a digital patient pathway for MS has been described [80]. Few studies have put into practise such systems, likely due to concerns about privacy, and the ethical implications of collecting and storing sensitive health information are significant. A digital twin is a virtual copy of a real patient and ML algorithms provided with ongoing data could suggest a treatment regime that will give the digital twin the best health outcome [81]. A recent study used clinical information to create a digital twin for MS patients and four types of ML models were trained to predict their disability status. The most accurate model was the Gradient Boosted classifier that was able to predict the transition of patients to moderate disability within 0–12 months. Analysis of these data could inform timely decision making around clinical interventions [81]. The future for digital twins in MS management involves long-term evaluation of the performance of such ML models. It has been suggested that multi-omics could be used to identify disease biomarkers in a large population and potentially reveal new therapeutic targets for personalised treatment [81].

5.2. Using AI to Estimate DMT Response

Personalised medicine for MS involves improving the prediction of treatment response using available clinical data, a process that could be more accurate using AI. Additionally, there are very few biomarkers that can predict an individual's response to various DMT. In the present study, deep learning models, that were a form of neural network, were trained to estimate an individual's treatment effect on disability progression [82]. Clinical information including demographics, EDSS scores and MRI lesion and volumetric measures were used. The models compared disability progression, using EDSS scores, for a patient under treatment or placebo to estimate an individual treatment effect. The model was able to identify and rank treatment effects among people with primary progressive MS receiving anti-CD20 antibody treatment. Similarly, the model could identify a subgroup of people more likely to respond to laquinimod, a medication with broad effects on leukocytes whose treatment effect was considered insufficient for drug approval [82]. This approach could be used to predict how specific treatments will impact an individual's disease progression. In the case of new medications for MS, like laquinimod, results could inform selection criteria to increase the efficiency of clinical trials for drug development and approval. The study was limited to predicting treatment effects over two to four years, where long-term observational data could identify those who may benefit from longer exposure to treatment.

5.3. AI-Facilitated Communication and Education in MS Care

Patient adherence can greatly influence the success of treatment, meaning effective communication between clinicians and PwMS and their caregivers is crucial. AI, specifically LLM, could be used to translate medical terminology into more accessible language and communicate crucial information about treatments to PwMS [83]. In addition, LLM could be used to tailor educational materials to the knowledge background of each person and provide tailored responses when professionals are not available. In a cohort of PwMS, responses to frequently asked questions provided by an AI chatbot, Chat-GPT, were

perceived to be more empathetic than responses from neurologists [84]. However, those who received higher education were less likely to prefer Chat-GPT responses, emphasising the importance of tailored communication that addresses the needs of each PwMS. AI could also facilitate effective communication between healthcare professionals involved in MS management via the translation of clinical data. Ophthalmology notes translated by Open AI ChatGPT-4.0 were considered more comprehensive and useful than original notes [85]. This highlights the potential use for AI in tailoring responses to individual characteristics to aid in MS care, although the implementation of these responses should consider human involvement. AI models could be used to complement clinicians in the delivery of education to PwMS; however, improved accuracy and validation of such models is required. AI models are promising in the field of personalised MS management but require further validation in the context of MS care and education.

6. AI-Assisted Fundamental Research Using Single-Cell Data

The use of AI for single-cell data analysis in MS research offers several advantages, namely, increasing the efficiency and standardisation of analysing the vast amounts of data generated by single-cell technologies. Furthermore, the recent appreciation of MS as a disease driven by a patient's immune signature and how this may facilitate precision medicine in MS necessitates efforts to optimise single-cell data analysis by applying ML methods [86]. Common single-cell technologies to study MS include flow cytometry, mass cytometry and single-cell RNA sequencing (scRNA-seq).

6.1. AI-Assisted Flow Cytometry Analysis

The use of AI to perform automated analysis of flow cytometry data is becoming increasingly important as the number of fluorescent antibody markers used in spectral flow cytometry panels for in-depth characterisation of immune cells reaches 40 markers [87]. Current methods often involve a combination of both manual gating analysis and unsupervised dimensionality reduction and clustering to study cell populations in PwMS. Garcia and colleagues analysed spectral flow cytometry data from 42 RRMS patients before and after ocrelizumab treatment by first manually gating the major T- and B-cell populations. They subsequently performed unsupervised dimensionality reduction via t-stochastic neighbour embedding (t-SNE) and clustering via the clustering algorithm FlowSOM [88] to identify distinct T-cell clusters, which they were able to relate to disease clinical activity [89]. Similarly, Waede and colleagues obtained spectral flow cytometry data from 23 RRMS patients and 10 healthy controls [90]. They first performed unsupervised dimensionality reduction by means of uniform manifold approximation and projection (UMAP) [91] and applied both the clustering algorithms FlowSOM and X-shift [92] to distinguish major immune cell populations. Afterwards, they manually gated the clusters of interest in order to quantify their relative proportions within the entire dataset. In a landmark study that aimed to define three distinct peripheral blood immune signatures of MS, Gross and colleagues used both manual gating and unsupervised dimensionality reduction and clustering via PhenoGraph [93]. They reasoned that the former allowed investigation of markers associated with small well-defined immune cell subsets, whilst the latter enabled identification of markers associated with complex immune cell phenotypes, that is, cell markers of differentiation, activation and maturation [86]. Ultimately, 149 and 235 markers were identified through manual gating and unsupervised analysis, respectively. Further, unsupervised cluster analysis characterised three distinct immunological subgroups based on their pattern of marker expression in a cohort of 309 PwMS.

6.2. AI Analysis of Mass Cytometry Data

In the field of mass cytometry, Diebold and colleagues adapted CellCnn, a CNN-based ML algorithm, to identify key immune cell subsets that were most relevant to the therapeutic effects of dimethyl fumarate (DMF) treatment [94]. For the input, mass cytometry data from 31 DMF-treated patients were used, with the output being either ‘responder’ or ‘non-responder’ depending on the presence or absence of evidence of clinical or radiological activity. Subsequent model training optimised weights to match the training dataset phenotype and the trained filter weights represented the molecular profiles of immune cell subsets. One subset of effector memory CD4⁺ T-cells was identified as being most strongly associated with treatment response, with a predictive accuracy of 79.14% (AUC = 0.85), and this finding was confirmed by spectral flow cytometry and automated analysis in a separate cohort (AUC = 0.84) [94].

6.3. Single-Cell RNA Sequencing Analysis by AI

For the analysis of scRNA-seq data, ML-based classifiers can be used to identify different cell populations in datasets as opposed to traditional methods of unsupervised clustering followed by manual inspection of cell populations for identification [95]. Esaulova and colleagues employed a neural network-based classifier with an input of gene counts obtained from published results using brain tissue microglia and an output of microglial cluster assignment [96,97]. They applied this classifier to CSF cells obtained from two RRMS patients and one patient with anti-myelin oligodendrocyte glycoprotein (MOG) disorder, another demyelinating disease of the CNS, and were able to identify a myeloid cell population as a pre-defined microglial cluster [96]. To avoid issues which may arise from using reference atlases based on different biological sources, Ostkamp and colleagues created another neural network-based tool, which enabled automated immune cell annotation of scRNA-seq datasets using CSF and found good correlation between their tool’s computed values and Seurat computed values, ranging from 0.843 to 0.964 [98].

6.4. Future Directions for Fundamental Research

There are more advanced techniques of AI-assisted single-cell analysis currently being used in other disease areas that could be applied to MS. Barone and colleagues developed T-REX, an unsupervised ML algorithm that combines UMAP and k-nearest neighbours (KNN) clustering algorithms and could identify key immune cell subsets representing <0.1% of the population in both spectral flow cytometry and mass cytometry samples [99]. By immunophenotyping cells which localised to regions of significant change in samples obtained over the course of rhinovirus infection, they were able to identify and quantify a small but critical population of virus-specific CD4⁺ T-cells. T-REX also outperformed PhenoGraph and FlowSOM in successfully identifying rare cells undergoing significant change in paired spectral flow cytometry samples [99]. Similarly, T-REX could be applied to MS cytometry datasets and used to monitor how individual patients respond to treatment or change during disease progression, potentially revealing key cell subsets not yet identified due to their low proportions in peripheral blood. Furthermore, the previously mentioned CellCnn algorithm for the analysis of mass cytometry samples can also be applied to flow cytometry and scRNA-seq data, increasing the efficiency of analysing highly multiparametric single-cell datasets obtained from large patient cohorts [100]. In the field of oncology, Fiser and colleagues applied hierarchical clustering analysis (HCA) to flow cytometry samples from 123 patients with acute lymphoblastic leukaemia (ALL) to characterise the leukemic cell population (i.e., minimal residual disease) and subsequently trained an SVM classifier to automatically detect the same population in follow-up samples from the same patient [101]. Similarly, using spectral flow cytometry, our lab previously

found that following cladribine treatment, regenerating effector memory CD4⁺ T-cell and central memory CD8⁺ T-cell subsets differed in both functional properties and immunophenotype in RRMS patients [102]. It would be of interest to train such a classifier to identify and quantify important regenerating cell subsets and whether this may inform a patient's response to therapy in a highly personalised fashion.

7. Discussion

Phenomenal progression has been made to incorporate AI in MS research, diagnosis, monitoring and treatment, with studies showing improved accuracy, efficiency, accessibility and enhanced knowledge when using ML. Indeed, AI can scrutinise data faster and more thoroughly than humans, as studies have shown that the AI program ChatGPT was faster to diagnose MS patients than clinicians, even though both had similar accuracy scores [103]. Interestingly, another study revealed that ChatGPT displayed greater empathy scores than clinicians by offering more support [84]. The results of these papers raise the question of whether AI techniques are better doctors than humans, especially when patient care and comfort is required. Whether patients would knowingly accept AI over clinicians is unknown. However, rather than replacing clinicians with AI, more research is required to understand how AI can be utilised to assist clinicians and PwMS. Because realistically, when patients interact face-to-face with clinicians, patient disease and background is better recognised, while AI relies on electronic data to understand patient disease prognosis [104].

Government bodies and private companies are now fuelling money into commercialising AI models to improve healthcare access for patients. Nevertheless, ethical concerns, such as population biases in training data, reduced human accountability, and potential monopolisation of AI tools, complicate AI integration in patient healthcare services [59]. Ethical and regulatory barriers complicate the creation and sharing of standardised datasets integrating MRI, biomarkers, and clinical data, which are essential for validating models, especially for neurodegeneration and progression [105,106]. Addressing these issues requires equitable data practices and multidisciplinary collaboration. Indeed, the World Health Organisation has recognised the need for ethical guidance and governance regarding large multi-modal models [107].

Another important consideration for the future of AI in MS is that patient symptom presentations are changing. Recent developments have shown that MS disease progression is a combination of relapse-associated worsening (RAW) and progression independent of relapse activity (PIRA) [108,109]. Indeed, current ML models have been trained to identify the 2017 McDonald diagnostic criteria; however, patients with atypical symptoms and disease presentations do not fit this—thus, AI models must be adapted to these changing factors [110]. Furthermore, AI model performance is highly dependent on training data which can result in biases and overfitting, where the model performs poorly on unseen data. Hence, future directions should mitigate this by cross-validation and utilising larger diverse datasets.

8. Conclusions

AI is increasingly becoming popular for its easy accessibility and ability to simplify tasks that require extensive knowledge and time. In this review, we explored how AI has impacted PwMS, whereby AI and ML tools have aided in diagnosing and monitoring MS patient prognosis using clinical data such as MRI, EDSS, OCT and MRS, essentially outperforming clinicians. Furthermore, AI-assisted approaches provide information about potential risks for MS and predict whether DMT's can improve patient outcomes. Using AI for drug discovery has shown potential to evaluate drug efficacy and identify if existing drugs can be repurposed for MS, thus accelerating its progress into clinical trials. Further-

more, the effect of AI on personalised treatment involves adaption of specific treatments for patients based on individual characteristics, which could improve responses to treatments. Finally, the capability for AI to analyse large single-cell datasets would also aid clinicians and researchers to find novel therapeutics and targets for disease. So far, our research indicates promising results for AI integration in MS healthcare; however, more studies are required to validate these models and ensure patients feel comfortable with AI-assisted support. Relatively soon, the diagnosis, monitoring and treatment landscape for PwMS will change with the integration of AI.

Author Contributions: Conceptualization, G.E.G., M.S.P. and L.Y.L.; writing—original draft preparation, M.S.P., L.Y.L., R.K.F., E.J.J. and S.M.; writing—review and editing, M.S.P., L.Y.L., R.K.F., E.J.J., S.M., F.M.-W., S.H. and G.E.G. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Jakimovski, D.; Bittner, S.; Zivadinov, R.; Morrow, S.A.; Benedict, R.H.; Zipp, F.; Weinstock-Guttman, B. Multiple sclerosis. *Lancet* **2024**, *403*, 183–202. [[CrossRef](#)]
2. Portaccio, E.; Magyari, M.; Havrdova, E.K.; Ruet, A.; Brochet, B.; Scalfari, A.; Di Filippo, M.; Tur, C.; Montalban, X.; Amato, M.P. Multiple sclerosis: Emerging epidemiological trends and redefining the clinical course. *Lancet Reg. Health Eur.* **2024**, *44*, 100977. [[CrossRef](#)] [[PubMed](#)]
3. Vargas, D.L.; Tyor, W.R. Update on disease-modifying therapies for multiple sclerosis. *J. Investig. Med.* **2017**, *65*, 883–891. [[CrossRef](#)] [[PubMed](#)]
4. Collins, C.; Dennehy, D.; Conboy, K.; Mikalef, P. Artificial intelligence in information systems research: A systematic literature review and research agenda. *Int. J. Inform. Manag.* **2021**, *60*, 102383. [[CrossRef](#)]
5. Tafti, D.; Ehsan, M.; Xixis, K.L. Multiple Sclerosis. In *StatPearls*; StatPearls Publishing: Treasure Island, FL, USA, 2025.
6. Gustavsen, S.; Olsson, A.; Sondergaard, H.B.; Andresen, S.R.; Sorensen, P.S.; Sellebjerg, F.; Oturai, A. The association of selected multiple sclerosis symptoms with disability and quality of life: A large Danish self-report survey. *BMC Neurol.* **2021**, *21*, 317. [[CrossRef](#)]
7. Khattap, M.G.; Abd Elaziz, M.; Hassan, H.; Elgarayhi, A.; Sallah, M. AI-based model for automatic identification of multiple sclerosis based on enhanced sea-horse optimizer and MRI scans. *Sci. Rep.* **2024**, *14*, 12104. [[CrossRef](#)] [[PubMed](#)]
8. Zhang, Y.-D.; Pan, C.; Sun, J.; Tang, C. Multiple sclerosis identification by convolutional neural network with dropout and parametric ReLU. *J. Comput. Sci.* **2018**, *28*, 1–10. [[CrossRef](#)]
9. Wang, S.H.; Tang, C.; Sun, J.; Yang, J.; Huang, C.; Phillips, P.; Zhang, Y.D. Multiple Sclerosis Identification by 14-Layer Convolutional Neural Network With Batch Normalization, Dropout, and Stochastic Pooling. *Front. Neurosci.* **2018**, *12*, 818. [[CrossRef](#)]
10. Cunill, V.; Massot, M.; Clemente, A.; Calles, C.; Andreu, V.; Núñez, V.; López-Gómez, A.; Díaz, R.M.; Jiménez, M.L.R.; Pons, J.; et al. Relapsing-Remitting Multiple Sclerosis Is Characterized by a T Follicular Cell Pro-Inflammatory Shift, Reverted by Dimethyl Fumarate Treatment. *Front. Immunol.* **2018**, *9*, 1097. [[CrossRef](#)]
11. Gabr, R.E.; Coronado, I.; Robinson, M.; Sujit, S.J.; Datta, S.; Sun, X.; Allen, W.J.; Lublin, F.D.; Wolinsky, J.S.; Narayana, P.A. Brain and lesion segmentation in multiple sclerosis using fully convolutional neural networks: A large-scale study. *Mult. Scler.* **2020**, *26*, 1217–1226. [[CrossRef](#)]
12. Coronado, I.; Gabr, R.E.; Narayana, P.A. Deep learning segmentation of gadolinium-enhancing lesions in multiple sclerosis. *Mult. Scler.* **2021**, *27*, 519–527. [[CrossRef](#)] [[PubMed](#)]
13. La Rosa, F.; Beck, E.S.; Maranzano, J.; Todea, R.A.; van Gelderen, P.; de Zwart, J.A.; Luciano, N.J.; Duyn, J.H.; Thiran, J.P.; Granziera, C.; et al. Multiple sclerosis cortical lesion detection with deep learning at ultra-high-field MRI. *NMR Biomed.* **2022**, *35*, e4730. [[CrossRef](#)] [[PubMed](#)]
14. Gentile, G.; Jenkinson, M.; Griffanti, L.; Luchetti, L.; Leoncini, M.; Inderyas, M.; Mortilla, M.; Cortese, R.; De Stefano, N.; Battaglini, M. BIANCA-MS: An optimized tool for automated multiple sclerosis lesion segmentation. *Hum. Brain Mapp.* **2023**, *44*, 4893–4913. [[CrossRef](#)] [[PubMed](#)]

15. Valverde, S.; Cabezas, M.; Roura, E.; Gonzalez-Villa, S.; Pareto, D.; Vilanova, J.C.; Ramio-Torrenta, L.; Rovira, A.; Oliver, A.; Llado, X. Improving automated multiple sclerosis lesion segmentation with a cascaded 3D convolutional neural network approach. *Neuroimage* **2017**, *155*, 159–168. [\[CrossRef\]](#)
16. Eshaghi, A.; Young, A.L.; Wijeratne, P.A.; Prados, F.; Arnold, D.L.; Narayanan, S.; Guttmann, C.R.G.; Barkhof, F.; Alexander, D.C.; Thompson, A.J.; et al. Identifying multiple sclerosis subtypes using unsupervised machine learning and MRI data. *Nat. Commun.* **2021**, *12*, 2078. [\[CrossRef\]](#)
17. Rostami, A.; Robatjazi, M.; Dareyni, A.; Ghorbani, A.R.; Ganji, O.; Siyami, M.; Raoofi, A.R. Enhancing classification of active and non-active lesions in multiple sclerosis: Machine learning models and feature selection techniques. *BMC Med. Imaging* **2024**, *24*, 345. [\[CrossRef\]](#)
18. Amini, A.; Shayganfar, A.; Amini, Z.; Ostovar, L.; HajiAhmadi, S.; Chitsaz, N.; Rabbani, M.; Kafieh, R. Deep learning for discrimination of active and inactive lesions in multiple sclerosis using non-contrast FLAIR MRI: A multicenter study. *Mult. Scler. Relat. Disord.* **2024**, *87*, 105642. [\[CrossRef\]](#)
19. Shekari, F.; Vard, A.; Adibi, I.; Danesh-Mobarhan, S. Investigating the feasibility of differentiating MS active lesions from inactive ones using texture analysis and machine learning methods in DWI images. *Mult. Scler. Relat. Disord.* **2024**, *82*, 105363. [\[CrossRef\]](#) [\[PubMed\]](#)
20. Dwyer, M.; Lyman, C.; Ferrari, H.; Bergsland, N.; Fuchs, T.A.; Jakimovski, D.; Schweser, F.; Weinstock-Guttman, B.; Benedict, R.H.B.; Riolo, J.; et al. DeepGRAI (Deep Gray Rating via Artificial Intelligence): Fast, feasible, and clinically relevant thalamic atrophy measurement on clinical quality T2-FLAIR MRI in multiple sclerosis. *Neuroimage Clin.* **2021**, *30*, 102652. [\[CrossRef\]](#)
21. Peters, S.; Kellermann, G.; Watkinson, J.; Gartner, F.; Huhndorf, M.; Sturmer, K.; Jansen, O.; Larsen, N. AI supported detection of cerebral multiple sclerosis lesions decreases radiologic reporting times. *Eur. J. Radiol.* **2024**, *178*, 111638. [\[CrossRef\]](#)
22. Barnett, M.; Wang, D.; Beadnall, H.; Bischof, A.; Brunacci, D.; Butzkueven, H.; Brown, J.W.L.; Cabezas, M.; Das, T.; Dugal, T.; et al. A real-world clinical validation for AI-based MRI monitoring in multiple sclerosis. *npj Digit. Med.* **2023**, *6*, 196. [\[CrossRef\]](#) [\[PubMed\]](#)
23. Roca, P.; Attye, A.; Colas, L.; Tucholka, A.; Rubini, P.; Cackowski, S.; Ding, J.; Budzik, J.F.; Renard, F.; Doyle, S.; et al. Artificial intelligence to predict clinical disability in patients with multiple sclerosis using FLAIR MRI. *Diagn. Interv. Imaging* **2020**, *101*, 795–802. [\[CrossRef\]](#) [\[PubMed\]](#)
24. Optic Neuritis Study, G. Multiple sclerosis risk after optic neuritis: Final optic neuritis treatment trial follow-up. *Arch. Neurol.* **2008**, *65*, 727–732. [\[CrossRef\]](#)
25. Dongil-Moreno, F.J.; Ortiz, M.; Pueyo, A.; Boquete, L.; Sanchez-Morla, E.M.; Jimeno-Huete, D.; Miguel, J.M.; Barea, R.; Vilades, E.; Garcia-Martin, E. Diagnosis of multiple sclerosis using optical coherence tomography supported by explainable artificial intelligence. *Eye* **2024**, *38*, 1502–1508. [\[CrossRef\]](#)
26. Ortiz, M.; Mallen, V.; Boquete, L.; Sanchez-Morla, E.M.; Cordon, B.; Vilades, E.; Dongil-Moreno, F.J.; Miguel-Jimenez, J.M.; Garcia-Martin, E. Diagnosis of multiple sclerosis using optical coherence tomography supported by artificial intelligence. *Mult. Scler. Relat. Disord.* **2023**, *74*, 104725. [\[CrossRef\]](#)
27. Kenney, R.C.; Liu, M.; Hasanaj, L.; Joseph, B.; Abu Al-Hassan, A.; Balk, L.J.; Behbehani, R.; Brandt, A.; Calabresi, P.A.; Frohman, E.; et al. The Role of Optical Coherence Tomography Criteria and Machine Learning in Multiple Sclerosis and Optic Neuritis Diagnosis. *Neurology* **2022**, *99*, e1100–e1112. [\[CrossRef\]](#)
28. Hernandez, M.; Ramon-Julvez, U.; Vilades, E.; Cordon, B.; Mayordomo, E.; Garcia-Martin, E. Explainable artificial intelligence toward usable and trustworthy computer-aided diagnosis of multiple sclerosis from Optical Coherence Tomography. *PLoS ONE* **2023**, *18*, e0289495. [\[CrossRef\]](#) [\[PubMed\]](#)
29. Wei, W.; Poirion, E.; Bodini, B.; Durrleman, S.; Ayache, N.; Stankoff, B.; Colliot, O. Predicting PET-derived demyelination from multimodal MRI using sketcher-refiner adversarial training for multiple sclerosis. *Med. Image Anal.* **2019**, *58*, 101546. [\[CrossRef\]](#)
30. Tolkach, Y.; Wolgast, L.M.; Damanakis, A.; Prylukhin, A.; Schallenberg, S.; Hulla, W.; Eich, M.L.; Schroeder, W.; Mukhopadhyay, A.; Fuchs, M.; et al. Artificial intelligence for tumour tissue detection and histological regression grading in oesophageal adenocarcinomas: A retrospective algorithm development and validation study. *Lancet Digit. Health* **2023**, *5*, e265–e275. [\[CrossRef\]](#) [\[PubMed\]](#)
31. Gehrung, M.; Crispin-Ortuzar, M.; Berman, A.G.; O'Donovan, M.; Fitzgerald, R.C.; Markowitz, F. Triage-driven diagnosis of Barrett's esophagus for early detection of esophageal adenocarcinoma using deep learning. *Nat. Med.* **2021**, *27*, 833–841. [\[CrossRef\]](#)
32. Lu, M.Y.; Chen, T.Y.; Williamson, D.F.K.; Zhao, M.; Shady, M.; Lipkova, J.; Mahmood, F. AI-based pathology predicts origins for cancers of unknown primary. *Nature* **2021**, *594*, 106–110. [\[CrossRef\]](#) [\[PubMed\]](#)
33. Nagpal, K.; Foote, D.; Liu, Y.; Chen, P.C.; Wulczyn, E.; Tan, F.; Olson, N.; Smith, J.L.; Mohtashamian, A.; Wren, J.H.; et al. Development and validation of a deep learning algorithm for improving Gleason scoring of prostate cancer. *NPJ Digit. Med.* **2019**, *2*, 48. [\[CrossRef\]](#) [\[PubMed\]](#)

34. Swiderska-Chadaj, Z.; Ma, Z.; Ing, N.; Markiewicz, T.; Lorent, M.; Cierniak, S.; Walts, A.E.; Knudsen, B.S.; Gertych, A. *Contextual Classification of Tumor Growth Patterns in Digital Histology Slides*; Springer: Cham, Switzerland, 2019; pp. 13–25.
35. Compston, A. Occasional essay: Multiple sclerosis in the digital age: ‘seeing through a glass darkly’. *J. Neurol. Neurosurg. Psychiatry* **2020**, *91*, 1017–1023. [[CrossRef](#)] [[PubMed](#)]
36. Kilic, A.K.; Kurne, A.T.; Oguz, K.K.; Soylemezoglu, F.; Karabudak, R. Mass lesions in the brain: Tumor or multiple sclerosis? Clinical and imaging characteristics and course from a single reference center. *Turk. Neurosurg.* **2013**, *23*, 728–735. [[CrossRef](#)]
37. Friedrich, M.; Struffert, T.; Dohmen, H.; Uhl, E. Two patients with cerebral lesions: Is it tumor or multiple sclerosis? *Illustrative cases J. Neurosurg. Case Lessons* **2022**, *4*, 8. [[CrossRef](#)]
38. Plantone, D.; Renna, R.; Sbardella, E.; Koudriavtseva, T. Concurrence of multiple sclerosis and brain tumors. *Front. Neurol.* **2015**, *6*, 40. [[CrossRef](#)]
39. Rocca, M.A.; Anzalone, N.; Storelli, L.; Del Poggio, A.; Cacciaguerra, L.; Manfredi, A.A.; Meani, A.; Filippi, M. Deep Learning on Conventional Magnetic Resonance Imaging Improves the Diagnosis of Multiple Sclerosis Mimics. *Investig. Radiol.* **2021**, *56*, 252–260. [[CrossRef](#)]
40. Llufriu, S.; Kornak, J.; Ratiney, H.; Oh, J.; Brennenman, D.; Cree, B.A.; Sampat, M.; Hauser, S.L.; Nelson, S.J.; Pelletier, D. Magnetic resonance spectroscopy markers of disease progression in multiple sclerosis. *JAMA Neurol.* **2014**, *71*, 840–847. [[CrossRef](#)]
41. Arnold, D.L.; Wolinsky, J.S.; Matthews, P.M.; Falini, A. The use of magnetic resonance spectroscopy in the evaluation of the natural history of multiple sclerosis. *J. Neurol. Neurosurg. Psychiatry* **1998**, *64* (Suppl. 1), S94–S101.
42. Eksi, Z.; Ozcan, M.E.; Cakiroglu, M.; Oz, C.; Aralasmak, A. Differentiation of multiple sclerosis lesions and low-grade brain tumors on MRS data: Machine learning approaches. *Neurol. Sci.* **2021**, *42*, 3389–3395. [[CrossRef](#)]
43. Hurwitz, B.J. The diagnosis of multiple sclerosis and the clinical subtypes. *Ann. Indian. Acad. Neurol.* **2009**, *12*, 226–230. [[CrossRef](#)] [[PubMed](#)]
44. Alowais, S.A.; Alghamdi, S.S.; Alsuhebany, N.; Alqahtani, T.; Alshaya, A.I.; Almohareb, S.N.; Aldaire, A.; Alrashed, M.; Bin Saleh, K.; Badreldin, H.A.; et al. Revolutionizing healthcare: The role of artificial intelligence in clinical practice. *BMC Med. Educ.* **2023**, *23*, 689. [[CrossRef](#)] [[PubMed](#)]
45. Khalifa, M.; Albadawy, M. Artificial Intelligence for Clinical Prediction: Exploring Key Domains and Essential Functions. *Comput. Methods Programs Biomed. Update* **2024**, *5*, 100148. [[CrossRef](#)]
46. Matinfar, F.; Tavakoli Golpaygani, A. A Fuzzy Expert System for Early Diagnosis of Multiple Sclerosis. *J. Biomed. Phys. Eng.* **2022**, *12*, 181–188. [[CrossRef](#)]
47. Brownlee, W.J.; Miller, D.H. Clinically isolated syndromes and the relationship to multiple sclerosis. *J. Clin. Neurosci.* **2014**, *21*, 2065–2071. [[CrossRef](#)]
48. Darvishi, S.; Hamidi, O.; Poorolajal, J. Prediction of Multiple sclerosis disease using machine learning classifiers: A comparative study. *J. Prev. Med. Hyg.* **2021**, *62*, E192–E199. [[CrossRef](#)]
49. Lötsch, J.; Schiffmann, S.; Schmitz, K.; Brunkhorst, R.; Lerch, F.; Ferreiros, N.; Wicker, S.; Tegeder, I.; Geisslinger, G.; Ultsch, A. Machine-learning based lipid mediator serum concentration patterns allow identification of multiple sclerosis patients with high accuracy. *Sci. Rep.* **2018**, *8*, 14884. [[CrossRef](#)] [[PubMed](#)]
50. Berek, K.; Bsteh, G.; Auer, M.; Di Pauli, F.; Zinganel, A.; Berger, T.; Deisenhammer, F.; Hegen, H. Cerebrospinal Fluid Findings in 541 Patients With Clinically Isolated Syndrome and Multiple Sclerosis: A Monocentric Study. *Front. Immunol.* **2021**, *12*, 675307. [[CrossRef](#)]
51. Schreiner, T.G.; Romanescu, C.; Popescu, B.O. The Blood-Brain Barrier-A Key Player in Multiple Sclerosis Disease Mechanisms. *Biomolecules* **2022**, *12*, 538. [[CrossRef](#)]
52. Gopalan, R. B-134 Artificial Intelligence (AI)-Driven Clinical Decision Support: Potential to Predict the Risk for Multiple Sclerosis. *Clin. Chem.* **2023**, *69*, hvad097-468. [[CrossRef](#)]
53. Tacchella, A.; Romano, S.; Ferraldeschi, M.; Salvetti, M.; Zaccaria, A.; Crisanti, A.; Grassi, F. Collaboration between a human group and artificial intelligence can improve prediction of multiple sclerosis course: A proof-of-principle study. *F1000Research* **2017**, *6*, 2172. [[CrossRef](#)] [[PubMed](#)]
54. Bonacchi, R.; Filippi, M.; Rocca, M.A. Role of artificial intelligence in MS clinical practice. *Neuroimage Clin.* **2022**, *35*, 103065. [[CrossRef](#)] [[PubMed](#)]
55. Kanber, B.; Nachev, P.; Barkhof, F.; Calvi, A.; Cardoso, J.; Cortese, R.; Prados, F.; Sudre, C.H.; Tur, C.; Ourselin, S.; et al. High-dimensional detection of imaging response to treatment in multiple sclerosis. *NPJ Digit. Med.* **2019**, *2*, 49. [[CrossRef](#)] [[PubMed](#)]
56. Praet, J.; Anderhalten, L.; Comi, G.; Horakova, D.; Ziemssen, T.; Vermersch, P.; Lukas, C.; van Leemput, K.; Steppe, M.; Aguilera, C.; et al. A future of AI-driven personalized care for people with multiple sclerosis. *Front. Immunol.* **2024**, *15*, 1446748. [[CrossRef](#)]
57. Lesjak, Ž.; Galimzianova, A.; Koren, A.; Lukin, M.; Pernuš, F.; Likar, B.; Špiclin, Ž. A Novel Public MR Image Dataset of Multiple Sclerosis Patients With Lesion Segmentations Based on Multi-rater Consensus. *Neuroinformatics* **2018**, *16*, 51–63. [[CrossRef](#)]

58. Muslim, A.M.; Mashohor, S.; Gawwam, G.A.; Mahmud, R.; Hanafi, M.B.; Alnuaimi, O.; Josephine, R.; Almutairi, A.D. Brain MRI dataset of multiple sclerosis with consensus manual lesion segmentation and patient meta information. *Data Brief.* **2022**, *42*, 108139. [\[CrossRef\]](#)
59. Amin, M.; Martínez-Heras, E.; Ontaneda, D.; Prados Carrasco, F. Artificial Intelligence and Multiple Sclerosis. *Curr. Neurol. Neurosci. Rep.* **2024**, *24*, 233–243. [\[CrossRef\]](#)
60. Placido, D.; Yuan, B.; Hjaltelin, J.X.; Zheng, C.; Haue, A.D.; Chmura, P.J.; Yuan, C.; Kim, J.; Umeton, R.; Antell, G.; et al. A deep learning algorithm to predict risk of pancreatic cancer from disease trajectories. *Nat. Med.* **2023**, *29*, 1113–1122. [\[CrossRef\]](#)
61. Kohli, M.D.; Summers, R.M.; Geis, J.R. Medical Image Data and Datasets in the Era of Machine Learning-Whitepaper from the 2016 C-MIMI Meeting Dataset Session. *J. Digit. Imaging* **2017**, *30*, 392–399. [\[CrossRef\]](#)
62. Pontillo, G.; Tommasin, S.; Cuocolo, R.; Petracca, M.; Petsas, N.; Ugga, L.; Carotenuto, A.; Pozzilli, C.; Iodice, R.; Lanzillo, R.; et al. A Combined Radiomics and Machine Learning Approach to Overcome the Clinicoradiologic Paradox in Multiple Sclerosis. *AJNR Am. J. Neuroradiol.* **2021**, *42*, 1927–1933. [\[CrossRef\]](#)
63. Ma, X.; Zhang, L.; Huang, D.; Lyu, J.; Fang, M.; Hu, J.; Zang, Y.; Zhang, D.; Shao, H.; Ma, L.; et al. Quantitative radiomic biomarkers for discrimination between neuromyelitis optica spectrum disorder and multiple sclerosis. *J. Magn. Reson. Imaging* **2019**, *49*, 1113–1121. [\[CrossRef\]](#) [\[PubMed\]](#)
64. Luo, X.; Piao, S.; Li, H.; Li, Y.; Xia, W.; Bao, Y.; Liu, X.; Geng, D.; Wu, H.; Yang, L. Multi-lesion radiomics model for discrimination of relapsing-remitting multiple sclerosis and neuropsychiatric systemic lupus erythematosus. *Eur. Radiol.* **2022**, *32*, 5700–5710. [\[CrossRef\]](#) [\[PubMed\]](#)
65. Inglese, F.; Kant, I.M.J.; Monahan, R.C.; Steup-Beekman, G.M.; Huizinga, T.W.J.; van Buchem, M.A.; Magro-Checa, C.; Ronen, I.; de Bresser, J. Different phenotypes of neuropsychiatric systemic lupus erythematosus are related to a distinct pattern of structural changes on brain MRI. *Eur. Radiol.* **2021**, *31*, 8208–8217. [\[CrossRef\]](#) [\[PubMed\]](#)
66. Magro Checa, C.; Cohen, D.; Bollen, E.L.E.M.; van Buchem, M.A.; Huizinga, T.W.J.; Steup-Beekman, G.M. Demyelinating disease in SLE: Is it multiple sclerosis or lupus? *Best. Pract. Res. Clin. Rheumatol.* **2013**, *27*, 405–424. [\[CrossRef\]](#)
67. Cesar, B.; Dwyer, M.G.; Shucard, J.L.; Polak, P.; Bergsland, N.; Benedict, R.H.B.; Weinstock-Guttman, B.; Shucard, D.W.; Zivadinov, R. Cognitive and White Matter Tract Differences in MS and Diffuse Neuropsychiatric Systemic Lupus Erythematosus. *Am. J. Neuroradiol.* **2015**, *36*, 1874–1883. [\[CrossRef\]](#)
68. Gauthier, S.A.; Mandel, M.; Guttmann, C.R.G.; Glanz, B.I.; Khoury, S.J.; Betensky, R.A.; Weiner, H.L. Predicting short-term disability in multiple sclerosis. *Neurology* **2007**, *68*, 2059–2065. [\[CrossRef\]](#)
69. Kurtzke, J.F. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). *Neurology* **1983**, *33*, 1444–1452. [\[CrossRef\]](#)
70. Piena, M.A.; Kroep, S.; Simons, C.; Fenwick, E.; Harty, G.T.; Wong, S.L.; van Hout, B.A. An Innovative Approach to Modelling the Optimal Treatment Sequence for Patients with Relapsing-Remitting Multiple Sclerosis: Implementation, Validation, and Impact of the Decision-Making Approach. *Adv. Ther.* **2022**, *39*, 892–908. [\[CrossRef\]](#)
71. Jackson, C.H.; Sharples, L.D.; Thompson, S.G.; Duffy, S.W.; Couto, E. Multistate Markov Models for Disease Progression with Classification Error. *J. R. Stat. Soc. Ser. D Stat.* **2003**, *52*, 193–209. [\[CrossRef\]](#)
72. Zeng, X.; Zhu, S.; Lu, W.; Liu, Z.; Huang, J.; Zhou, Y.; Fang, J.; Huang, Y.; Guo, H.; Li, L.; et al. Target identification among known drugs by deep learning from heterogeneous networks. *Chem. Sci.* **2020**, *11*, 1775–1797. [\[CrossRef\]](#)
73. Gönen, M. Predicting drug-target interactions from chemical and genomic kernels using Bayesian matrix factorization. *Bioinformatics* **2012**, *28*, 2304–2310. [\[CrossRef\]](#)
74. Xia, Z.; Wu, L.Y.; Zhou, X.; Wong, S.T. Semi-supervised drug-protein interaction prediction from heterogeneous biological spaces. *BMC Syst. Biol.* **2010**, *4* (Suppl. 2), S6. [\[CrossRef\]](#) [\[PubMed\]](#)
75. deAndrés-Galiana, E.J.; Bea, G.; Fernández-Martínez, J.L.; Saligan, L.N. Analysis of defective pathways and drug repositioning in Multiple Sclerosis via machine learning approaches. *Comput. Biol. Med.* **2019**, *115*, 103492. [\[CrossRef\]](#) [\[PubMed\]](#)
76. Palacios, R.; Goni, J.; Martinez-Forero, I.; Iranzo, J.; Sepulcre, J.; Melero, I.; Villoslada, P. A Network Analysis of the Human T-Cell Activation Gene Network Identifies Jagged1 as a Therapeutic Target for Autoimmune Diseases. *PLoS ONE* **2007**, *2*, e1222. [\[CrossRef\]](#) [\[PubMed\]](#)
77. Agarwal, S.; Dugar, D.; Sengupta, S. Ranking Chemical Structures for Drug Discovery: A New Machine Learning Approach. *J. Chem. Inf. Model.* **2010**, *50*, 716–731. [\[CrossRef\]](#)
78. Khamis, M.A.; Gomaa, W.; Ahmed, W.F. Machine learning in computational docking. *Artif. Intell. Med.* **2015**, *63*, 135–152. [\[CrossRef\]](#)
79. Inojosa, H.; Voigt, I.; Wenk, J.; Ferber, D.; Wiest, I.; Antweiler, D.; Weicken, E.; Gilbert, S.; Kather, J.N.; Akgun, K.; et al. Integrating large language models in care, research, and education in multiple sclerosis management. *Mult. Scler.* **2024**, *30*, 1392–1401. [\[CrossRef\]](#)
80. Wenk, J.; Voigt, I.; Inojosa, H.; Schlieter, H.; Ziemssen, T. Building digital patient pathways for the management and treatment of multiple sclerosis. *Front. Immunol.* **2024**, *15*, 1356436. [\[CrossRef\]](#)

81. Palaniappan, R.; Siva, R. *Revolutionizing MS Rehabilitation with Digital Twins and Machine Learning: A Promising Path to Precision Medicine*; Springer: Cham, Switzerland, 2024; pp. 182–192.
82. Falet, J.R.; Durso-Finley, J.; Nichyporuk, B.; Schroeter, J.; Bovis, F.; Sormani, M.P.; Precup, D.; Arbel, T.; Arnold, D.L. Estimating individual treatment effect on disability progression in multiple sclerosis using deep learning. *Nat. Commun.* **2022**, *13*, 5645. [\[CrossRef\]](#)
83. Inojosa, H.; Gilbert, S.; Kather, J.N.; Proschmann, U.; Akgün, K.; Ziemssen, T. Can ChatGPT explain it? Use of artificial intelligence in multiple sclerosis communication. *Neurol. Res. Pract.* **2023**, *5*, 48. [\[CrossRef\]](#)
84. Maida, E.; Moccia, M.; Palladino, R.; Borriello, G.; Affinito, G.; Clerico, M.; Repice, A.M.; Di Sapio, A.; Iodice, R.; Spiezia, A.L.; et al. ChatGPT vs. neurologists: A cross-sectional study investigating preference, satisfaction ratings and perceived empathy in responses among people living with multiple sclerosis. *J. Neurol.* **2024**, *271*, 4057–4066. [\[CrossRef\]](#)
85. Balas, M.; Kaplan, A.J.; Esmail, K.; Saleh, S.; Sharma, R.A.; Yan, P.; Arjmand, P. Translating ophthalmic medical jargon with artificial intelligence: A comparative comprehension study. *Can. J. Ophthalmol.* **2024**. [\[CrossRef\]](#) [\[PubMed\]](#)
86. Gross, C.C.; Schulte-Mecklenbeck, A.; Steinberg, O.V.; Wirth, T.; Lauks, S.; Bittner, S.; Schindler, P.; Baranzini, S.E.; Groppa, S.; Bellmann-Strobl, J.; et al. Multiple sclerosis endophenotypes identified by high-dimensional blood signatures are associated with distinct disease trajectories. *Sci. Transl. Med.* **2024**, *16*, eade8560. [\[CrossRef\]](#) [\[PubMed\]](#)
87. Park, L.M.; Lannigan, J.; Jaimes, M.C. OMIP-069: Forty-Color Full Spectrum Flow Cytometry Panel for Deep Immunophenotyping of Major Cell Subsets in Human Peripheral Blood. *Cytom. A* **2020**, *97*, 1044–1051. [\[CrossRef\]](#) [\[PubMed\]](#)
88. Van Gassen, S.; Callebaut, B.; Van Helden, M.J.; Lambrecht, B.N.; Demeester, P.; Dhaene, T.; Saeys, Y. FlowSOM: Using self-organizing maps for visualization and interpretation of cytometry data. *Cytom. A* **2015**, *87*, 636–645. [\[CrossRef\]](#)
89. Garcia, A.; Dugast, E.; Shah, S.; Morille, J.; Lebrun-Frenay, C.; Thouvenot, E.; De Sèze, J.; Le Page, E.; Vukusic, S.; Maurousset, A.; et al. Immune Profiling Reveals the T-Cell Effect of Ocrelizumab in Early Relapsing-Remitting Multiple Sclerosis. *Neurol. Neuroimmunol. Neuroinflamm.* **2023**, *10*, e200091. [\[CrossRef\]](#)
90. Waede, M.; Voss, L.F.; Kingo, C.; Moeller, J.B.; Elkjaer, M.L.; Illes, Z. Longitudinal analysis of peripheral immune cells in patients with multiple sclerosis treated with anti-CD20 therapy. *Ann. Clin. Transl. Neurol.* **2024**, *11*, 2657–2672. [\[CrossRef\]](#)
91. McInnes, L.; Healy, J. UMAP: Uniform Manifold Approximation and Projection for Dimension Reduction. *arXiv* **2018**, arXiv:1802.03426. [\[CrossRef\]](#)
92. Samusik, N.; Good, Z.; Spitzer, M.H.; Davis, K.L.; Nolan, G.P. Automated mapping of phenotype space with single-cell data. *Nat. Methods* **2016**, *13*, 493–496. [\[CrossRef\]](#)
93. Levine, J.H.; Simonds, E.F.; Bendall, S.C.; Davis, K.L.; Amir, E.A.D.; Tadmor, M.D.; Litvin, O.; Fienberg, H.G.; Jager, A.; Zunder, E.R.; et al. Data-Driven Phenotypic Dissection of AML Reveals Progenitor-like Cells that Correlate with Prognosis. *Cell* **2015**, *162*, 184–197. [\[CrossRef\]](#)
94. Diebold, M.; Galli, E.; Kopf, A.; Sanderson, N.S.R.; Callegari, I.; Benkert, P.; Gonzalo Núñez, N.; Ingelfinger, F.; Herms, S.; Cichon, S.; et al. High-dimensional immune profiling identifies a biomarker to monitor dimethyl fumarate response in multiple sclerosis. *Proc. Natl. Acad. Sci. USA* **2022**, *119*, e2205042119. [\[CrossRef\]](#) [\[PubMed\]](#)
95. Abdelaal, T.; Michielsen, L.; Cats, D.; Hoogduin, D.; Mei, H.; Reinders, M.J.T.; Mahfouz, A. A comparison of automatic cell identification methods for single-cell RNA sequencing data. *Genome Biol.* **2019**, *20*, 194. [\[CrossRef\]](#) [\[PubMed\]](#)
96. Esaulova, E.; Cantoni, C.; Shchukina, I.; Zaitsev, K.; Bucelli, R.C.; Wu, G.F.; Artyomov, M.N.; Cross, A.H.; Edelson, B.T. Single-cell RNA-seq analysis of human CSF microglia and myeloid cells in neuroinflammation. *Neurol. Neuroimmunol. Neuroinflamm.* **2020**, *7*, e732. [\[CrossRef\]](#) [\[PubMed\]](#)
97. Sankowski, R.; Böttcher, C.; Masuda, T.; Geirsdottir, L.; Sagar Sindram, E.; Seredenina, T.; Muhs, A.; Scheiwe, C.; Shah, M.J.; Heiland, D.H. Mapping microglia states in the human brain through the integration of high-dimensional techniques. *Nat. Neurosci.* **2019**, *22*, 2098–2110. [\[CrossRef\]](#)
98. Ostkamp, P.; Deffner, M.; Schulte-Mecklenbeck, A.; Wunsch, C.; Lu, I.N.; Wu, G.F.; Goelz, S.; De Jager, P.L.; Kuhlmann, T.; Gross, C.C.; et al. A single-cell analysis framework allows for characterization of CSF leukocytes and their tissue of origin in multiple sclerosis. *Sci. Transl. Med.* **2022**, *14*, eadc9778. [\[CrossRef\]](#)
99. Barone, S.M.; Paul, A.G.; Muehling, L.M.; Lannigan, J.A.; Kwok, W.W.; Turner, R.B.; Woodfolk, J.A.; Irish, J.M. Unsupervised machine learning reveals key immune cell subsets in COVID-19, rhinovirus infection, and cancer therapy. *Elife* **2021**, *10*, e64653. [\[CrossRef\]](#)
100. Arvaniti, E.; Claassen, M. Sensitive detection of rare disease-associated cell subsets via representation learning. *Nat. Commun.* **2017**, *8*, 14825. [\[CrossRef\]](#)
101. Fišer, K.; Sieger, T.; Schumich, A.; Wood, B.; Irving, J.; Mejstříková, E.; Dworzak, M.N. Detection and monitoring of normal and leukemic cell populations with hierarchical clustering of flow cytometry data. *Cytom. A* **2012**, *81*, 25–34. [\[CrossRef\]](#)
102. Ford, R.K.; Juillard, P.; Hawke, S.; Grau, G.E.; Marsh-Wakefield, F. Cladribine Reduces Trans-Endothelial Migration of Memory T Cells across an In Vitro Blood-Brain Barrier. *J. Clin. Med.* **2022**, *11*, 6006. [\[CrossRef\]](#)

103. Patel, M.A.; Villalobos, F.; Shan, K.; Tardo, L.M.; Horton, L.A.; Sguigna, P.V.; Blackburn, K.M.; Munoz, S.B.; Moog, T.M.; Smith, A.D.; et al. Generative artificial intelligence versus clinicians: Who diagnoses multiple sclerosis faster and with greater accuracy? *Mult. Scler. Relat. Disord.* **2024**, *90*, 105791. [\[CrossRef\]](#)
104. Lee, J. Is Artificial Intelligence Better Than Human Clinicians in Predicting Patient Outcomes? *J. Med. Internet Res.* **2020**, *22*, e19918. [\[CrossRef\]](#) [\[PubMed\]](#)
105. Bradshaw, A.; Hughes, N.; Vallez-Garcia, D.; Chokoshvili, D.; Owens, A.; Hansen, C.; Emmert, K.; Maetzler, W.; Killin, L.; Barnes, R.; et al. Data sharing in neurodegenerative disease research: Challenges and learnings from the innovative medicines initiative public-private partnership model. *Front. Neurol.* **2023**, *14*, 1187095. [\[CrossRef\]](#) [\[PubMed\]](#)
106. Giehl, K.; Mutsaerts, H.-J.; Aarts, K.; Barkhof, F.; Caspers, S.; Chetelat, G.; Colin, M.-E.; Düzel, E.; Frisoni, G.B.; Ikram, M.A.; et al. Sharing brain imaging data in the Open Science era: How and why? *Lancet Digit. Health* **2024**, *6*, e526–e535. [\[CrossRef\]](#) [\[PubMed\]](#)
107. Sonicki, Z. Large multi-modal models—The present or future of artificial intelligence in medicine? *Croat. Med. J.* **2024**, *65*, 1–2. [\[CrossRef\]](#)
108. Ciccarelli, O.; Barkhof, F.; Calabrese, M.; De Stefano, N.; Eshaghi, A.; Filippi, M.; Gasperini, C.; Granziera, C.; Kappos, L.; Rocca, M.A.; et al. Using the Progression Independent of Relapse Activity Framework to Unveil the Pathobiological Foundations of Multiple Sclerosis. *Neurology* **2024**, *103*, e209444. [\[CrossRef\]](#)
109. Lublin, F.D.; Häring, D.A.; Ganjgahi, H.; Ocampo, A.; Hatami, F.; Čuklina, J.; Aarden, P.; Dahlke, F.; Arnold, D.L.; Wiendl, H.; et al. How patients with multiple sclerosis acquire disability. *Brain* **2022**, *145*, 3147–3161. [\[CrossRef\]](#)
110. Rocca, M.A.; Preziosa, P.; Barkhof, F.; Brownlee, W.; Calabrese, M.; De Stefano, N.; Granziera, C.; Ropele, S.; Toosy, A.T.; Vidal-Jordana, A.; et al. Current and future role of MRI in the diagnosis and prognosis of multiple sclerosis. *Lancet Reg. Health Eur.* **2024**, *44*, 100978. [\[CrossRef\]](#)

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.